期刊文献+

乙酰肝素酶在膀胱移行细胞癌中的表达及临床意义

Expression of heparanase in the bladder transitional cell carcinoma and its clinical significance
下载PDF
导出
摘要 目的:探讨乙酰肝素酶(Heparanase,HPA)在膀胱移行细胞癌中的表达及临床意义。方法:应用逆转录-聚合酶链反应(RT-PCR)及免疫组织化学方法检测68例膀胱移行细胞癌、24例癌旁组织、15例正常膀胱组织中HPA mRNA的水平及蛋白表达定位,并结合患者临床病理指标及预后进行分析。结果:膀胱移行细胞癌中HPA mRNA检出阳性41例(60.3%),24例癌旁组织中阳性1例(4.2%),15例正常膀胱组织中全部阴性,分别与癌组织组比较差异有统计学意义(P<0.01),HPA mRNA的表达在膀胱移行细胞癌不同病理分级、临床分期及淋巴结转移与否分组中显著不同(P<0.01)。免疫组织化学结果显示,HPA定位于细胞质及细胞核,阳性率为77.9%(53例),在膀胱移行细胞癌淋巴结转移与否分组中显著不同(P<0.01)。结论:HPA在膀胱移行细胞癌的生长浸润、侵袭转移中可能发挥重要作用,可为膀胱移行细胞癌生物学行为和预后的判断提供较客观指标。 Objective:To explore the expression of heparanase(HPA) and its correlation with the clinical pathological features and angiogenesis in bladder transitional cell carcinomas Methods: HPA mRNA level was detected with RT-PCR methods and immunohistochemistry staining in 68 bladder cancer and 24 adjacent cancer tissue and 15 normal bladder tissue. Expression of HPA mRNA was analyzed with their relation to the clinical pathological features in bladder cancer. Results:The positive of HPA mRNA was 60. 3%(41/68) ,4.2%(1/24) ,0% (0/15) in 68 bladder cancer and 24 adjacent cancer tissue and 15 normal bladder tissue respectively. The expression of HPA mRNA has much correlation with pathological grades and lymph node metastasis of bladder cancer. The positive of HPA protein was 77.9% (53/68) in bladder cancer. The expression of HPA protein has much correlation with lymph node metastasis. Conclusion: HPA may play an important role in the growth, invasion and metastasis of bladder cancer. The expressions of HPA was an useful marker of the biological behavior of bladder cancer and an independent prognosis factor for the patients with bladder cancer.
出处 《临床泌尿外科杂志》 2008年第4期289-291,共3页 Journal of Clinical Urology
关键词 膀胱移行细胞癌 乙酰肝素酶 免疫组织化学 Bladder transitional cell carcinoma Heparanase Immunohistochemistry
  • 相关文献

参考文献10

  • 1Pectasides D, Pectasides M, Economopoulos T. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer[J]. Cancer Treat Rev, 2006,32 (6): 456-470.
  • 2Miao H Q, Liu H, Navarro E, et al. Development of heparanase inhibitors for anti-cancer therapy[J]. Curr Med Chem, 2006, 13(18) :2101-2111.
  • 3于冬梅,阎晓初,郭德玉,柳凤轩,刘丽梅.VEGF和nm23蛋白在膀胱移行细胞癌中表达及临床意义[J].第三军医大学学报,2006,28(21):2180-2182. 被引量:16
  • 4Fjeldstad K, Kolset S O. Decreasing the metastatic potential in cancers-targeting the heparan sulfate proteoglycans[J]. Curr Drug Targets, 2005, 6(6): 665-682.
  • 5Takaoka M, Naomoto Y, Ohkawa T, et al. Heparanase expression correlates with invasion and poor prognosis in gastric cancers[J]. Lab Invest, 2003, 83 (5): 613-622.
  • 6Cohen I,Pappo O,Elkin M, et al. Heparanase promotes growth, angiogenesis and survival of primary breast tumors[J]. Int J Cancer, 2006, 118(7): 1609-1617.
  • 7Dafni H,Cohen B,Ziv K, et al. The role of heparanase in lymph node metastatic dissemination., dynamic contrast-enhanced MRI of Eb lymphoma in mice[J]. Neoplasia, 2005, 7(3): 224-233.
  • 8Gohji K, Okamoto M, Kitazawa S, et al. Heparanase protein and gene expression in bladder cancer[J]. J Urol, 2001, 166(4): 1286-1290.
  • 9Joyce J A,Freeman C, Meyer M N, et al. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer[J]. Oncogene, 2005, 24(25): 4037-4051.
  • 10Zetser A, Bashenko Y, Edovitsky E, et al. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation[J]. CancerRes, 2006, 1455-1463.

二级参考文献13

  • 1徐培元,赵华.浅表性膀胱移行细胞癌组织中Survivin的表达[J].郑州大学学报(医学版),2005,40(4):659-661. 被引量:2
  • 2FOURNIER H N,ALBIGES-RIZO C,BLOCK M R.New insights into Nm23 control of cell adhesion and migration[J].J Bioenerg Biomembr,2003,35(1):81-87.
  • 3SPIESS P E,CZERNIAK B.Dual-track pathway of carcinogenesis:practical implications[J].Arch Parhol Lab Med,2006,130(6):844-852.
  • 4HEIMANN R,FERGUSON D J,HELLMAN S.The relationship between nm23,angiogenesis,and the metastatic proclivity of node-negative breast cancer[J].Cancer Res,1998,58(13):2766-2771.
  • 5FOLKMAN J,KLAGSBRUN M.Angiogenic factors[J].Science,1987,235(4787):442-447.
  • 6YAMAGUCHI A,URANO T,GOI T,et al.Expression of human nm23-H1 and nm23-H2 proteins in hepatocellular carcinoma[J].Cancer,1994,73(9):2280-2284.
  • 7HOLLINGSWORTH H C,KOHN E C,STEINBERG S M,et al.Tumor angiogenesis in advanced stage ovarian carcinoma[J].Am J Pathol,1995,147(1):33-41.
  • 8DVORAK H F,BROWN L F,DETMAR M,et al.Vascular permeability factor/vascular endothelial growth factor,microvascular hyperpermeability,and angiogenesis[J].Am J Pathol,1995,146(5):1029-1039.
  • 9SANTIN A D,HERMONAT P L,RAVAGGI A,et al.Secretion of vascular endothelial growth factor in ovarian cancer[J].Eur J Gynaecol Oncol,1999,20(3):177-181.
  • 10HICKLIN D J,ELLIS L M.Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis[J].J Clin Oncol,2005,23(5):1011-1027.

共引文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部